We evaluated at eight cancer types with high frequencies of CDKN2A VAR and a significant influence on patient outcomes: ESCA (Esophageal carcinoma), KIRC (Kidney renal clear cell carcinoma), KIRP (Kidney renal papillary cell carcinoma), LUAD (Lung adenocarcinoma), MESO (Mesothelioma), pancreatic (PAAD), SARC (Sarcoma) and Stomach adenocarcinoma (STAD). This evidence concerns the gene CDKN2A and gastric adenocarcinoma.